Key result
Olmesartan and telmisartan lower DBP up to ~14 mmHg, beating losartan in Stage I hypertension.
Why the study?
Does olmesartan or telmisartan improve blood pressure and metabolic parameters compared to losartan in patients with Stage I hypertension?
RCT (n=60)
Open-label
Computer-generated table of random numbers
No
Does olmesartan or telmisartan improve blood pressure and metabolic parameters compared to losartan in patients with Stage I hypertension?
Absolute Event Rate: 13.8% vs 7.2%
p-value: p=<0.001
In patients with Stage I hypertension, olmesartan provides superior blood pressure reduction, while telmisartan offers the most favorable metabolic profile regarding fasting blood glucose and lipids.
Supports preferring olmesartan or telmisartan over losartan for greater diastolic BP reduction in Stage I hypertension; extends comparative ARB efficacy data.
OBJECTIVES: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose. MATERIALS AND METHODS: This was a randomized, open-label, parallel-group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg). Blood pressure (BP) was assessed at an interval of 2 weeks for 3 months. Fasting blood glucose (FBG) and lipid profile were estimated at baseline and then at 12 weeks. RESULTS: < 0.02) after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low-density lipoproteins decreased significantly after 12-week treatment with olmesartan and telmisartan. CONCLUSIONS: The most efficacious drug in reducing BP is Olmesartan whereas telmisartan and losartan show equal efficacy. Telmisartan shows the most favorable effects on FBG and lipid profile.
No takes yet. Share an insight, caveat, or question.
Kalikar et al. (2017) conducted an RCT in Stage I hypertension (n=60). Olmesartan and Telmisartan vs. Losartan 50 mg once daily was evaluated on Change in sitting cuff diastolic BP (DBP) from baseline to 12 weeks (p=<0.001). Olmesartan and telmisartan significantly reduced diastolic blood pressure by 13.8 mmHg and 12.2 mmHg respectively, compared to a 7.2 mmHg reduction with losartan in Stage I hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: